Thymalfasin

Phase 2Small molecule

SSciClone Pharmaceuticals

Thymalfasin is one of 152 small molecule programs targeting Vaccine Response. It is currently in Phase 2.

Indications

Total Trials

Active Trials

151

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vaccine ResponseRecruiting

ChemoradiotherapyActive, not recruiting

Gastroesophageal Junction AdenocarcinomaRecruiting

Esophageal CancerUnknown status

Colorectal CancerRecruiting

Vaccine ResponsePhase 1

Recruiting

ChemoradiotherapyPhase 2

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Recruiting

Esophageal CancerPhase 2

Unknown status

Colorectal CancerPhase 2

Recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

24 2

Fudr

Pfizer

Phase 3

16 3

Tecentriq

Roche

Phase 3

6 4

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

8 5

Decadron

AAspen Global Incorporated

Phase 3

7 6

Botensilimab

AAgenus Inc.

Phase 3

10 7

Balstilimab

AAgenus Inc.

Phase 3

10 8

Zanzalintinib

Merck & Co.

Phase 3

1 9

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 3

2 10

Serplulimab

Shanghai Henlius Biotech

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Vaccine Response

NCT06821100

Q3 2027

Phase 2Active, not recruiting

Chemoradiotherapy

NCT06056804

Q4 2027

Phase 2Recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06461910

Phase 2Recruiting

Colorectal Cancer

NCT06829355

Q1 2029

Phase 2Not yet recruiting

Esophageal Cancer

NCT07780721

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Unknown status·SSciClone Pharmaceuticals·Phase 2·NCT02906150·140 enrolled

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.

Withdrawn·ZZhejiang Provincial People's Hospital·Phase 2·NCT02542930

Hepatocellular Carcinoma2 trials

A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

Completed·SSciClone Pharmaceuticals·Phase 2·NCT00082082

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

Unknown status·JJia Fan·Phase 4·NCT02281266·360 enrolled

Small Cell Lung Cancer2 trials

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Unknown status·SSciClone Pharmaceuticals·Phase 1/2·NCT02906163·188 enrolled

Abscopal Effect for Metastatic Small Cell Lung Cancer

Withdrawn·ZZhejiang Provincial People's Hospital·Phase 2·NCT02542137

Chemoradiotherapy2 trials

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Unknown status·—··NCT06024356·26 enrolled

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Active, not recruiting·—·Phase 2·NCT06056804·20 enrolled

Esophageal Cancer2 trials

SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer

Unknown status·HHangzhou Cancer Hospital·Phase 2·NCT02545751·29 enrolled

Exploratory, Single-Arm, Multicenter Clinical Study of Adebrelimab Combined With Thymalfasin and Chemotherapy as Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Not yet recruiting·TThe Affiliated Hospital of Putian University·Phase 2·NCT07780721·31 enrolled

9 more indications

Hepatitis C1 trial

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Completed·SSciClone Pharmaceuticals·Phase 3·NCT00039962·500 enrolled

Colorectal Cancer1 trial

"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

Recruiting·—·Phase 2·NCT06829355·52 enrolled

Advanced Refractory Solid Tumors1 trial

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT05790447·60 enrolled

COVID-191 trial

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

Terminated·RRhode Island Hospital·Phase 2·NCT04487444·56 enrolled

Metastatic Colorectal Cancer1 trial

Abscopal Effect for Metastatic Colorectal Cancer

Withdrawn·ZZhejiang Provincial People's Hospital·Phase 2·NCT02535988

Gastroesophageal Junction Adenocarcinoma1 trial

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting·ZZekuan Xu·Phase 2·NCT06461910·30 enrolled

Renal Dialysis1 trial

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

Completed·—·Phase 2·NCT04428008·262 enrolled

Effectiveness1 trial

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001036·12 enrolled

Vaccine Response1 trial

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

Recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT06821100·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Thymalfasin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thymalfasin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thymalfasin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SciClone Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSciClone Pharmaceuticals

Thymalfasin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q1 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Hepatocellular Carcinoma2 trials

Small Cell Lung Cancer2 trials

Chemoradiotherapy2 trials

Esophageal Cancer2 trials

Hepatitis C1 trial

Colorectal Cancer1 trial

Advanced Refractory Solid Tumors1 trial

COVID-191 trial

Metastatic Colorectal Cancer1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Renal Dialysis1 trial

Effectiveness1 trial

Vaccine Response1 trial

References

Drug Info

Quick Facts

Related News